ArticleArthritis care & research2025
Association of Higher Levels of High-Sensitivity C-Reactive Protein With Future Development of Psoriatic Arthritis in Psoriasis: A Prospective Cohort Study.
Article in Arthritis care & research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Biologic Therapies on the Risk of Progression from Psoriasis to Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies.American journal of clinical dermatology · 2026Pooled it
- Clinical, hematologic, and inflammatory factors associated with psoriatic arthritis in a Chinese hospital-based study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveWe aimed to assess whether high-sensitivity C-reactive protein (hsCRP) levels could predict the development of psoriatic arthritis (PsA) in patients with psoriasis.
methodsWe analyzed data from a prospective cohort of patients with psoriasis without PsA at enrollment. Participants were assessed annually by a rheumatologist for signs and symptoms of PsA. Information on patient demographics, psoriasis features, medications and musculoskeletal symptoms was collected. hsCRP levels were measured in serum samples collected at baseline using standard commercial assays. The association between hsCRP levels and risk of development of PsA was assessed using multivariable Cox proportional hazards model adjusted for age, sex, psoriasis severity and duration, nail lesions, body mass index (BMI), fatigue, and medication use.
resultsA total of 589 patients with psoriasis observed from 2006 to 2019 were analyzed. During the follow up period, 57 patients developed PsA. The mean level of hsCRP was 3.1 ± 5.5 mg/L (hsCRP levels in patients with incident PsA, 5.4 ± 13.1 mg/L). Significantly higher levels of hsCRP at baseline were found in patients with arthralgia, obesity, and in women. Higher hsCRP levels were associated with future development of PsA in multivariable analyses (hazard ratio 1.04; 95% confidence interval 1.01-1.07; P = 0.007). Similar effect size was seen in men and women. No significant interaction was found between hsCRP and sex or BMI.
conclusionHigher levels of systemic inflammation, as measured by hsCRP levels, are associated with future development of PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.